Manufacturing & Packaging

Parties will establish a Center of Excellence in CMIC’s NJ plant.

Northern Ireland hub undergoes $85 million expansion.

CDMO predicts that its facilities can now potentially produce over $400 million in annual revenue.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

CDMO will financially commit $10.6 million toward semi-solid and non-sterile liquid production.

CDMO’s Heidelberg facility will house the newly-completed manufacturing line.

The report also references a CAGR of 7.8% through that year.

Packaging manufacturers partner up in effort to help tackle pharma’s demand for recyclable packaging.

Site aims to advance regenerative medicines on a global scale.

The conference will focus on the full breadth of commercialization strategies and operations.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

Manufacturing capacity of company’s High Point facility now doubles as a result.

The trend is continuing for brands and even for some specialty products.

CTDMO is reportedly the first to provide this aforementioned service, which spans through commercialization.

Cold chain packaging and logistics provider expands GDP-compliant bonded warehousing services.

Plant will handle end-to-end services in effort to accelerate project time.

Two months after tornado strikes North Carolina facility, manufacturing will undergo a phased approach, with full capacity expected by the end of 2023.

CDMO purchases branded sachet-packaging machine for commercial manufacturing.

The insulated shipping containers can be used in the pharma industry and are reportedly environmentally friendly.

Deal to focus on development and commercialization in key emerging countries.

Deal aims to provide diabetes treatment to patients across the continent.

SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.

CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.

The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.

Financial commitment is intended to benefit development and commercialization of new products.

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

Expansion allows facility to provide E2E services in one location, including commercial manufacturing.

The company will occupy approximately 62,000 square feet of the new building.

The plant— dedicated to cell and gene therapy development—welcomes additional warehouse space, and aims to meet commercial needs.